欧州のシングルセルマルチオミクス市場 - 分析と予測（2023年～2033年）

欧州のシングルセルマルチオミクスの市場規模は、2023年に3億5,000万米ドルとなりました。

同市場は、2033年には17億1,000万米ドルに達すると予測され、予測期間の2023年～2033年のCAGRは17.23%で成長する見込みです。同市場は、シングルセルRNAシーケンス（Sc-RNA）を利用した大規模ゲノム研究の普及、疾患スクリーニングや診断におけるシングルセルマルチオミクスアプローチを利用した個別化医療へのシフト、医薬品開発におけるシングルセルマルチオミクスの採用の高まりなど、いくつかの要因によって成長を遂げています。

欧州のシングルセルマルチオミクス市場は、ゲノム研究の進展と個別化ヘルスケアの採用増加により大きな成長を遂げています。研究者はシングルセルマルチオミクス技術を活用し、疾患の分子メカニズムについてより深い洞察を得ることで、より正確な診断と治療を実現しています。さらに、これらの技術は、高度に的を絞った治療アプローチを可能にすることで、医薬品開発に革命をもたらしつつあります。強固なヘルスケアインフラと研究能力を有する欧州は、シングルセルマルチオミクス導入の最前線にあります。学術機関、バイオテクノロジー企業、ヘルスケア事業体のコラボレーションがイノベーションを促進し、これらの最先端技術の応用範囲を拡大し、市場の拡大に寄与しています。

当レポートでは、欧州のシングルセルマルチオミクス市場について調査し、市場の概要とともに、業界の見通し、COVID-19の影響、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

エグゼクティブサマリー

調査範囲

調査手法

第1章 市場

• 世界市場の展望
• 市場概要
• 業界の展望
  • 規制の枠組み
  • 特許分析
  • 主要な動向
  • 機会の評価
  • 製品のベンチマーク
  • 臨床試験
• COVID-19の影響
• ビジネスダイナミクス
  • 影響分析
  • ビジネスの促進要因
  • ビジネスの抑制要因
  • ビジネスの機会

第2章 欧州

• 欧州
  • 主な調査結果と機会の評価
  • 市場力学
  • 市場規模と予測

第3章 市場-競合ベンチマーキングと企業プロファイル

• 競合ベンチマーキング
  • 主要な戦略と展開
  • 市場シェア分析
  • 成長シェア分析
  • 企業のビジュアルグラフィックス
  • マルチオミクスエコシステムの活躍企業
• 企業プロファイル
  • Menarini Group
  • QIAGEN NV
  • Rarecells Diagnostics
  • Scipio Bioscience
  • Singleron Biotechnologies

List of Figures

• Figure 1: An Overview of Single-Cell Multi-Omics Sequencing Technologies
• Figure 2: Single-Cell Multi-Omics Market, Impact Analysis
• Figure 3: Single-Cell Multi-Omics Market (by Region), $Billion, 2022 and 2033
• Figure 4: Single-Cell Multi-Omics Market: Research Methodology
• Figure 5: Primary Research Methodology
• Figure 6: Bottom-Up Approach (Segment-Wise Analysis)
• Figure 7: Top-Down Approach (Segment-Wise Analysis)
• Figure 8: Single-Cell Multi-Omics Market, Patent Analysis (by Country), January 2018- March 2023
• Figure 9: Single-Cell Multi-Omics Market, Patent Analysis (by Year), January 2018-December2022
• Figure 10: Single-Cell Multi-Omics Market, Key Trends, Market Shift, 2022-2033
• Figure 11: Single-Cell Multi-Omics Market, Impact Analysis
• Figure 12: Global Data for Rare Diseases, 2020
• Figure 13: Companies Using Multi-Omics Approach in Research and Development of Drugs and Vaccines
• Figure 14: Advantages of Multi-Omics in Drug Discovery and Development
• Figure 15: Cost of Single Cell Sequencing (by Company)
• Figure 16: Some of the Advancements in Single-Cell Metabolomics
• Figure 17: Single-Cell Multi-Omics Market Share (by Region)
• Figure 18: Europe Single-Cell Multi-Omics Market, Incremental Opportunity (by Country), $Million, 2023-2033
• Figure 19: Europe Single-Cell Multi-Omics Market, $Billion, 2022-2033
• Figure 20: Europe Single-Cell Multi-Omics Market (by Country), % Share, 2022 and 2033
• Figure 21: Germany Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 22: Italy Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 23: U.K. Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 24: Spain Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 25: France Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 26: Rest-of-Europe Single-Cell Multi-Omics Market, $Million, 2022-2033
• Figure 27: Single-Cell Multi-Omics Market, Number of Key Developments and Strategies, January 2018-March 2023
• Figure 28: Funding Activities, January 2018-March 2023
• Figure 29: New Offerings, January 2018-March 2023
• Figure 30: Mergers and Acquisitions, January 2018-March 2023
• Figure 31: Partnership, Collaboration, and Business expansion, January 2018-March 2023
• Figure 32: Single-Cell Multi-Omics Market, Company Revenue Share Analysis, $Billion, 2022
• Figure 33: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Application), 2023-2033
• Figure 34: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Omics Type), 2023-2033
• Figure 35: Single-Cell Multi-Omics Market, Growth-Share Matrix (by Product Type), 2023-2033
• Figure 36: Single Cell Multi Omics Market, Visual Graphics of the Companies
• Figure 37: Menarini Silicon Biosystems: Product Portfolio
• Figure 38: QIAGEN NV: Product Portfolio
• Figure 39: QIAGEN NV: Overall Financials, $Million, 2020-2022
• Figure 40: QIAGEN NV: Net Revenue (by Segment), $Million, 2020-2022
• Figure 41: QIAGEN NV: Net Revenue (by Region), $Million, 2020-2022
• Figure 42: QIAGEN NV: R&D Expenditure, $Million, 2020-2020
• Figure 43: Rarecells Diagnostics: Product Portfolio
• Figure 44: Scipio Bioscience: Product Portfolio
• Figure 45: Singleron Biotechnologies: Product Portfolio

List of Tables

• Table 1: Single-Cell Multi-Omics Market, Key Developments Analysis, January 2018-March 2023
• Table 2: Key Questions Answered in the Report
• Table 3: Single-Cell Multi-Omics Market: Global Regulatory Organization
• Table 4: Single-Cell Multi-Omics Market, Product Benchmarking
• Table 5: Single-Cell Multi-Omics Market, Ongoing Clinical Trials
• Table 6: Single-Cell Multi-Omics Platforms Used in the Diagnosis of Disease
• Table 7: Recent Collaborations between Technology Providers and Life Sciences Companies
• Table 8: Europe Single-Cell Multi-Omics Market Dynamics, Impact Analysis
• Table 9: Multi-Omics Ecosystem Active Players

“The Europe Single-Cell Multi-Omics Market Expected to Reach $1.71 Billion by 2033.”

Introduction to Europe Single-Cell Multi-Omics Market

The Europe single-cell multi-omics market was valued at $0.35 billion in 2023 and is expected to reach $1.71 billion by 2033, growing at a CAGR of 17.23% during the forecast period 2023-2033. The market experiences growth due to several factors, including the increasing prevalence of large-scale genomics studies utilizing single-cell RNA sequencing (Sc-RNA), a shift towards personalized medicine using the single-cell multi-omics approach in disease screening and diagnostics, and the rising adoption of single-cell multi-omics in drug development.

Market Introduction

The Europe Single-Cell Multi-Omics Market is experiencing significant growth due to the advancements in genomics research and the increasing adoption of personalized healthcare. Researchers are leveraging single-cell multi-omics technologies to gain deeper insights into the molecular mechanisms of diseases, resulting in more precise diagnostics and treatments. Furthermore, these technologies are revolutionizing drug development by enabling highly targeted therapeutic approaches. Europe, with its robust healthcare infrastructure and research capabilities, is at the forefront of embracing single-cell multi-omics. Collaborations among academic institutions, biotech companies, and healthcare entities are driving innovation and expanding the scope of applications for these cutting-edge technologies, contributing to the market's expansion.

Market Segmentation:

Segmentation 1: by Country

• Germany
• U.K.
• France
• Italy
• Spain
• Rest-of-Europe

How can this report add value to an organization?

Growth/Marketing Strategy: The Europe single-cell multi-omics market has seen major development by key players operating in the market, such as new offerings, partnerships, collaboration, and joint ventures.

Competitive Strategy: The Europe single-cell multi-omics market has witnessed growth in recent years; as the field of single-cell multi-omics grows, it has witnessed increased collaboration between researchers, academic institutions, and industry partners to drive innovation and commercialization of these technologies. Single-cell multi-omics technologies are already being used in various applications, such as cancer research, immunology, and neuroscience. As the technologies continue to improve, they may be applied to other areas of research, such as developmental biology and stem cell research.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and regional presence.

Some of the prominent names in this market are:

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Market

• 1.1. Global Market Outlook
  • 1.1.1. Product Definition
  • 1.1.2. Inclusion and Exclusion Criteria
• 1.2. Market Overview
  • 1.2.1. Key Findings
  • 1.2.2. Current Market Scenario
    • 1.2.2.1. For Researchers
    • 1.2.2.2. For Diagnostics
• 1.3. Industry Outlook
  • 1.3.1. Regulatory Framework
  • 1.3.2. Patent Analysis
    • 1.3.2.1. Awaited Technological Developments
    • 1.3.2.2. Patent Filing Trend (by Country)
    • 1.3.2.3. Patent Filing Trend (by Year)
  • 1.3.3. Key Trends
    • 1.3.3.1. Advancements in Imaging Techniques for Single-Cell Sequencing
    • 1.3.3.2. Use of Artificial Intelligence (AI) and Machine Learning (ML) in Single-Cell Multi-Omics
    • 1.3.3.3. Increased Development of Advanced Solution Based on Single-Cell Technology
  • 1.3.4. Opportunity Assessment
  • 1.3.5. Product Benchmarking
  • 1.3.6. Clinical Trials
• 1.4. COVID-19 Impact
  • 1.4.1. Pre-COVID-19
  • 1.4.2. During COVID-19
  • 1.4.3. Post COVID-19
• 1.5. Business Dynamics
  • 1.5.1. Impact Analysis
  • 1.5.2. Business Drivers
    • 1.5.2.1. Rising Number of Large-Scale Genomics Studies Leveraging Single-Cell RNA Sequencing (Sc-RNA)
    • 1.5.2.2. Use of Single-Cell Multi-Omics Approach for Screening and Diagnostics of Diseases Leading to Shift Toward Personalized Medicine
    • 1.5.2.3. Increasing Use of Single-Cell Multi-Omics for Drug Development
    • 1.5.2.4. Collaborations among Technology Providers and Life Sciences Companies for Accelerating the Research in Single-Cell Multi-Omics
  • 1.5.3. Business Restraints
    • 1.5.3.1. High Cost of Single-Cell Analysis and Sequencing
    • 1.5.3.2. Limited Availability of Large Online Data Storage and Analysis Platforms
  • 1.5.4. Business Opportunities
    • 1.5.4.1. Expansion into New Research Applications, Such as Single-Cell Metabolomics
    • 1.5.4.2. Increasing Adoption of Genomic-Based Medicine in Emerging Nations

2. Europe

• 2.1. Europe
  • 2.1.1. Key Findings and Opportunity Assessment
  • 2.1.2. Market Dynamics
    • 2.1.2.1. Impact Analysis
  • 2.1.3. Market Sizing and Forecast
    • 2.1.3.1. Europe Single-Cell Multi-Omics Market (by Country)
      • 2.1.3.1.1. Germany
      • 2.1.3.1.2. Italy
      • 2.1.3.1.3. U.K.
      • 2.1.3.1.4. Spain
      • 2.1.3.1.5. France
      • 2.1.3.1.6. Rest-of-Europe

3. Markets - Competitive Benchmarking & Company Profiles

• 3.1. Competitive Benchmarking
  • 3.1.1. Key Strategies and Developments
    • 3.1.1.1. Funding Activities
    • 3.1.1.2. New Offerings
    • 3.1.1.3. Mergers and Acquisitions
    • 3.1.1.4. Partnership, Collaboration, and Business Expansion
  • 3.1.2. Market Share Analysis
  • 3.1.3. Growth Share Analysis
    • 3.1.3.1. By Application
    • 3.1.3.2. By Omics Type
    • 3.1.3.3. By Product Type
  • 3.1.4. Visual Graphics of the Companies
  • 3.1.5. Multi-Omics Ecosystem Active Players
• 3.2. Company Profiles
  • 3.2.1. Menarini Group
    • 3.2.1.1. Company Overview
    • 3.2.1.2. Role of Menarini Group in the Single-Cell Multi-Omics Market
    • 3.2.1.3. Analyst Perspective
  • 3.2.2. QIAGEN NV
    • 3.2.2.1. Company Overview
    • 3.2.2.2. Role of QIAGEN NV in the Single-Cell Multi-Omics Market
    • 3.2.2.3. Financials
    • 3.2.2.4. Analyst Perspective
  • 3.2.3. Rarecells Diagnostics
    • 3.2.3.1. Company Overview
    • 3.2.3.2. Role of Rarecells Diagnostics in the Single-Cell Multi-Omics Market
    • 3.2.3.3. Analyst Perspective
  • 3.2.4. Scipio Bioscience
    • 3.2.4.1. Company Overview
    • 3.2.4.2. Role of Scipio Bioscience in the Single-Cell Multi-Omics Market
    • 3.2.4.3. Analyst Perspective
  • 3.2.5. Singleron Biotechnologies
    • 3.2.5.1. Company Overview
    • 3.2.5.2. Role of Singleron Biotechnologies in the Single-Cell Multi-Omics Market
    • 3.2.5.3. Recent Developments
    • 3.2.5.4. Analyst Perspective